Table 2:

Diagnostic performance of ¹¹C-MET PET in subgroups of brain tumors

Analysis	No. of Studies (pts)	Independent Estimates (95% CI)		LR (95% CI)
		Sensitivity	Specificity	LR+	LR−
Design
Prospective	4 (156)	0.91 (0.84–0.95)	0.92 (0.78–0.97)	11.49 (3.87–34.08)	0.10 (0.06–0.18)
Retrospective	7 (260)	0.91 (0.81–0.96)	0.84 (0.73–0.90)	5.50 (3.18–9.51)	0.11 (0.05–0.24)
PET measurement
Qualitative	5 (189)	0.93 (0.87–0.96)	0.85 (0.73–0.92)	6.10 (3.34–11.15)	0.08 (0.04–0.16)
Quantitative	6 (227)	0.89 (0.79–0.94)	0.89 (0.74–0.96)	8.38 (3.07–22.88)	0.13 (0.07–0.25)
PET or PET/CT
PET	7 (232)	0.86 (0.78–0.91)	0.89 (0.72–0.96)	7.96 (2.75–23.00)	0.16 (0.10–0.26)
PET/CT	4 (184)	0.95 (0.89–0.97)	0.86 (0.74–0.93)	6.62 (3.48–12.59)	0.06 (0.03–0.13)
Malignant grade
Low	5 (97)a	0.90 (0.76–0.96)	0.88 (0.77–0.94)	7.44 (3.68–15.02)	0.12 (0.05–0.30)
High	7 (132)a	0.98 (0.75–1.00)	0.88 (0.75–0.95)	8.51 (3.78–19.17)	0.02 (0.00–0.34)
NS	4 (153)	0.87 (0.79–0.93)	0.87 (0.69–0.96)	6.93 (2.52–19.04)	0.15 (0.08–0.26)
Disease status
SPBT	2 (85)	0.95 (0.85–0.98)	0.83 (0.65–0.93)	5.49 (2.47–12.21)	0.07 (0.02–0.20)
SRBT	8 (238)	0.92 (0.83–0.97)	0.87 (0.75–0.93)	6.81 (3.39–13.69)	0.09 (0.04–0.21)
NS	2 (93)	0.88 (0.78–0.94)	0.95 (0.71–0.99)	16.69 (2.47–112.66)	0.13 (0.07–0.24)
Histology
Glioma	9 (292)b	0.92 (0.85–0.95)	0.87 (0.76–0.93)	7.01 (3.67–13.38)	0.10 (0.05–0.18)
Nonglioma and NS	4 (182)b	0.88 (0.79–0.93)	0.83 (0.66–0.92)	5.07 (2.39–10.79)	0.14 (0.08–0.28)

Note:—NS indicates not separable; pts, patients.

^aPatients with non-neoplastic lesions in 5 studies^{23–25,30,43} were used for both low and high grade subgroups.

^bPatients with non-neoplastic lesions in 2 studies^29,41 were used for both glioma and non-glioma subgroups.